Glenmark Pharmaceutical’s Antiviral Drug Hits the Mark in Small, Phase III COVID-19 Study

An antiviral drug developed by Glenmark Pharmaceuticals boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.

On Wednesday, Glenmark announced Phase III results that showed its antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of COVID-19 compared to placebo.